Abstract
The metabolic syndrome (MetS) is a cluster of metabolic conditions associated to abdominal obesity, such as elevated blood pressure, impaired glucose tolerance, insulin resistance, elevated triglycerides, and low high-density lipoprotein cholesterol concentrations. Each of the associated conditions has an independent effect, but clustering together they become synergistic, making the risk of developing cardiovascular disease (CVD) greater. There is a big debate as to whether the MetS alone or its associated health conditions are more important for CVD incidence and mortality or whether prevention and/or treatment of the MetS will reduce CVD incidence and mortality. This article reviews the evidence that demonstrates that individuals with the MetS are at increased risk for CVD incidence and mortality and discusses these debated issues.
Keywords: Metabolic syndrome, cardiovascular disease, coronary heart disease, diabetes mellitus, lipids, blood pressure.
Current Vascular Pharmacology
Title:Metabolic Syndrome and Cardiometabolic Risk Factors
Volume: 11 Issue: 6
Author(s): Emilia Papakonstantinou, Vaia Lambadiari, George Dimitriadis and Antonis Zampelas
Affiliation:
Keywords: Metabolic syndrome, cardiovascular disease, coronary heart disease, diabetes mellitus, lipids, blood pressure.
Abstract: The metabolic syndrome (MetS) is a cluster of metabolic conditions associated to abdominal obesity, such as elevated blood pressure, impaired glucose tolerance, insulin resistance, elevated triglycerides, and low high-density lipoprotein cholesterol concentrations. Each of the associated conditions has an independent effect, but clustering together they become synergistic, making the risk of developing cardiovascular disease (CVD) greater. There is a big debate as to whether the MetS alone or its associated health conditions are more important for CVD incidence and mortality or whether prevention and/or treatment of the MetS will reduce CVD incidence and mortality. This article reviews the evidence that demonstrates that individuals with the MetS are at increased risk for CVD incidence and mortality and discusses these debated issues.
Export Options
About this article
Cite this article as:
Papakonstantinou Emilia, Lambadiari Vaia, Dimitriadis George and Zampelas Antonis, Metabolic Syndrome and Cardiometabolic Risk Factors, Current Vascular Pharmacology 2013; 11 (6) . https://dx.doi.org/10.2174/15701611113116660176
DOI https://dx.doi.org/10.2174/15701611113116660176 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Depression in Older Persons with Mobility Limitations
Current Pharmaceutical Design Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry Obesity, Hypertension and Hypercholesterolemia as Risk Factors for Atherosclerosis Leading to Ischemic Events
Current Medicinal Chemistry Clinical Aspects of Melatonin in the Acute Coronary Syndrome
Current Vascular Pharmacology The Promise of Plant Polyphenols as the Golden Standard Skin Anti-Inflammatory Agents
Current Drug Metabolism Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies
Current Pharmaceutical Design Molecular Remodeling of the Insulin Receptor Pathway by Thiazolidinediones in Type 2 Diabetes Mellitus: A Brief Review
Protein & Peptide Letters Atherosclerotic Process in Seroreverter Children and Adolescents Exposed to Fetal Antiretroviral Therapy
Current HIV Research Circulating Endothelial Progenitor Cells as Biomarkers for Prediction of Cardiovascular Outcomes
Current Medicinal Chemistry Ligand Based Validated Comparative Chemometric Modeling and Pharmacophore Mapping of Aurone Derivatives as Antimalarial Agents
Current Computer-Aided Drug Design Leptin and the Cardiovascular System: A Review
Recent Patents on Cardiovascular Drug Discovery Psychological Stress in Pathogenesis of Essential Hypertension
Current Hypertension Reviews Hyperglycaemia and Vitamin D: A Systematic Overview
Current Diabetes Reviews Tissue Doppler Imaging in Coronary Heart Diseases and Heart Failure: An Up to Date
Recent Patents on Medical Imaging The Effects of Pemafibrate in Japanese Patients with Type 2 Diabetes Receiving HMG-CoA Reductase Inhibitors
Endocrine, Metabolic & Immune Disorders - Drug Targets Biomarkers in Atrial Fibrillation and Heart Failure
Current Medicinal Chemistry Central Hemodynamics in Risk Assessment Strategies: Additive Value Over and Above Brachial Blood Pressure
Current Pharmaceutical Design Polyphenols: Biological Activities, Molecular Targets, and the Effect of Methylation
Current Molecular Pharmacology Role of Mechanical Stress in Monocytes / Macrophages: Implications for Atherosclerosis
Current Vascular Pharmacology Edtorial [Hot topic: Glucocorticoids from Chemistry to Clinics (Executive Editor: Fortunato Vesce)]
Current Pharmaceutical Design